ArticleNature medicine2024

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Roger Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.